These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 16611561)

  • 21. Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant.
    Horner AA; Raz E
    Clin Immunol; 2000 Apr; 95(1 Pt 2):S19-29. PubMed ID: 10729234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity.
    Ranasinghe C; Ramshaw IA
    Expert Rev Vaccines; 2009 Sep; 8(9):1171-81. PubMed ID: 19722891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
    Sloat BR; Cui Z
    Vaccine; 2006 Sep; 24(40-41):6405-13. PubMed ID: 16828937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal adjuvants.
    Stevceva L; Ferrari MG
    Curr Pharm Des; 2005; 11(6):801-11. PubMed ID: 15777234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of new candidates as mucosal vaccine adjuvant in TNF family cytokines.
    Kayamuro H; Yoshioka Y; Abe Y; Katayama K; Arita S; Nomura T; Yoshikawa T; Itoh N; Kamada H; Tsunoda S; Tsutsumi Y
    Adv Exp Med Biol; 2011; 691():299-304. PubMed ID: 21153334
    [No Abstract]   [Full Text] [Related]  

  • 26. CpG oligodeoxynucleotides as mucosal adjuvants.
    Iho S; Maeyama J; Suzuki F
    Hum Vaccin Immunother; 2015; 11(3):755-60. PubMed ID: 25751765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bypassing luminal barriers, delivery to a gut addressin by parenteral targeting elicits local IgA responses.
    McKenzie BS; Corbett AJ; Johnson S; Brady JL; Pleasance J; Kramer DR; Boyle JS; Jackson DC; Strugnell RA; Lew AM
    Int Immunol; 2004 Nov; 16(11):1613-22. PubMed ID: 15466913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
    Revaz V; Zurbriggen R; Moser C; Schiller JT; Ponci F; Bobst M; Nardelli-Haefliger D
    Antiviral Res; 2007 Oct; 76(1):75-85. PubMed ID: 17617476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvants for porcine reproductive and respiratory syndrome virus vaccines.
    Charerntantanakul W
    Vet Immunol Immunopathol; 2009 May; 129(1-2):1-13. PubMed ID: 19157569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
    Klinman DM; Klaschik S; Sato T; Tross D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular adjuvants for mucosal immunity.
    Toka FN; Pack CD; Rouse BT
    Immunol Rev; 2004 Jun; 199():100-12. PubMed ID: 15233729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can mucosal adjuvants contribute to the induction of immunological memory induced via unconjugated T-cell-independent antigens?
    Romeu B; Gonzalez E; Lastre M; Pérez O
    J Drug Target; 2012 Jul; 20(6):502-8. PubMed ID: 22632258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mucosal immunity with implications for use in developing a new generation of vaccines].
    Osek J; Truszczyński M
    Postepy Hig Med Dosw; 1995; 49(4):469-86. PubMed ID: 8657643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of oral vaccines].
    Matsubara A; Shimizu Y; Karamatsu K; Yasutomi Y
    Nihon Rinsho; 2008 Oct; 66(10):1873-8. PubMed ID: 18939484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for improved formulation and delivery of DNA vaccines to veterinary target species.
    van Drunen Littel-van den Hurk S; Babiuk SL; Babiuk LA
    Immunol Rev; 2004 Jun; 199():113-25. PubMed ID: 15233730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens in vivo.
    Zhang L; Zhang M; Li J; Cao T; Tian X; Zhou F
    Res Vet Sci; 2008 Dec; 85(3):495-502. PubMed ID: 18359498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maturation of mucosal immune responses and influence of maternal antibodies.
    Jónsdóttir I
    J Comp Pathol; 2007 Jul; 137 Suppl 1():S20-6. PubMed ID: 17559864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.